Jak

Xcell Biosciences Announces New Scientific and Business Advisory Board

Retrieved on: 
Mercredi, mars 27, 2024
Biotechnology, Technology, Health, General Health, Oncology, Health Technology, Research, Software, Artificial Intelligence, Genetics, Science, PCR, Organization, EWF, Prostate cancer, Juno Therapeutics, Synthetic biology, Trex, University, CBO, Jak, Biology, Bayer, Investment, Therapy, Mountaineering, Intergalactic, AVATAR, SUGEN, Hematology, Bio-Rad Laboratories, Medicine

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.

Key Points: 
  • Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
  • The board will provide valuable expertise to help the company achieve its goals in the therapeutics market.
  • Prior to Affini-T, Jak was head of health venture investments for Leaps by Bayer, a leading corporate venture fund.
  • Jak also served as CEO of CytoSen Therapeutics, where he developed natural killer immune cell therapies for oncology indications.

Immortals of Aveum Arrives Today, Combining a Cinematic Single–Player Story With Spellbinding FPS Combat

Retrieved on: 
Mardi, août 22, 2023
Electronic Games, Consumer Electronics, Technology, Entertainment, Software, Sigil, Weapon, Electronic Arts, Traveller Deluxe Edition, Magic, Immortal, EA, Xbox Series X and Series S, Hope, Multimedia, Firefly, Forest, Lily Cowles, FPS, AAA, Deluxe, PlayStation 5, Lichdom: Battlemage, Ascendant, Steam, Special edition, Video game, Hand, COVID-19, Jak

"We built a world-class team, learned Unreal Engine 5, and created an amazing combat system and story from scratch – all through the adversity of Covid.

Key Points: 
  • "We built a world-class team, learned Unreal Engine 5, and created an amazing combat system and story from scratch – all through the adversity of Covid.
  • Beyond combat, the world of Aveum offers a unique fantasy universe with rich storytelling, puzzles and unique locations.
  • “Ascendant Studios have cast FPS conventions to the wayside with Immortals of Aveum,” said Jeff Gamon, General Manager of EA Partners.
  • For more information and to stay up to date on Immortals of Aveum, visit https://www.ea.com/games/immortals-of-aveum/immortals-of-aveum .

Rising Star and Rapper Jufu Teams up With Magic FPS Game, Immortals of Aveum, to Premier New Single

Retrieved on: 
Vendredi, août 18, 2023
Entertainment, Consumer Electronics, Technology, Music, Licensing (Entertainment), Internet, Electronic Games, Sigil, Midway Arcade Treasures Deluxe Edition, Partnership, Magic, Life, Immortal, EA, Xbox Series X and Series S, Hope, The World's Number One, Flat-Out, All-Time Great Stock Car Racing Book, Multimedia, Social media, Deluxe, PlayStation 5, Electronic Arts, Steam, Special edition, Video game, Hand, Jak

View the full release here: https://www.businesswire.com/news/home/20230818456820/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230818456820/en/
    Watch the Immortals of Aveum™ launch trailer, set to the brand new single "All Time Great" by rising rapper and musician Jufu.
  • (Graphic: Business Wire)
    This high-powered track by Brooklyn-based rap star Jufu, is set to exhilarating gameplay footage of Jak and his fellow Immortals, Lucium’s elite order of magic-wielders.
  • Social media star and rapper Julian Jeanmarie, better known as Jufu to his 3.1 Million fans on TikTok, is an up-and-coming artist from Brooklyn, New York.
  • Jufu's on a similar journey and his music really resonated with us as an expression of Jak's personality and swagger.

EA and Ascendant Studios Unveil Immortals of Aveum™, an All-New Single Player Magic Shooter Launching July 20, 2023

Retrieved on: 
Jeudi, avril 13, 2023
Software, Teens, Consumer Electronics, Technology, Electronic Games, Consumer, Other Consumer, Entertainment, Suit, Electronic Arts, Midway Arcade Treasures Deluxe Edition, Magic, Life, EA, Xbox Series X and Series S, Multimedia, Dead Island Reveal Trailer, Firefly, FPS, AAA, Deluxe, PlayStation 5, Pearson, Ascendant, House, PlayStation, Steam, Special edition, BAFTA, Video game, Immortal, Jak

Today, Electronic Arts Inc. (NASDAQ: EA) and Ascendant Studios announced that Immortals of Aveum™, a groundbreaking single-player, first-person magic shooter, will be released on July 20, 2023 on PlayStation 5, Xbox Series X|S and PC via EA App, Steam and Epic Games Store.

Key Points: 
  • Today, Electronic Arts Inc. (NASDAQ: EA) and Ascendant Studios announced that Immortals of Aveum™, a groundbreaking single-player, first-person magic shooter, will be released on July 20, 2023 on PlayStation 5, Xbox Series X|S and PC via EA App, Steam and Epic Games Store.
  • Combining a modern story within a fantasy setting, the world of Aveum is filled with unforgettable characters, fast-paced action and spell-based combat that defies FPS conventions.
  • EA Play Pro members will get access to the Deluxe edition on EA App starting July 20, 2023.
  • For more information and to stay up to date on Immortals of Aveum, visit https://www.ea.com/games/immortals-of-aveum/immortals-of-aveum .

 Sierra Oncology Reports Second Quarter 2021 Results

Retrieved on: 
Jeudi, août 5, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Company, Momelotinib, Fast Track, Jak, Clinical trial, Research, U.S. Securities and Exchange Commission, Bachelor of Medicine, Bachelor of Surgery, Anemia, Private Securities Litigation Reform Act, European Hematology Association, Reata Pharmaceuticals, Gilead, Platelet, Security (finance), Patient, US Foods, COVID-19, BRD4, Board, Cancer, Harpoon, Food and Drug Administration, GAAP, Week, Risk, Genentech, Doctor of Philosophy, Exercise, Survival, AstraZeneca, NDA, Director, Income, Therapy, Safety, Ruxolitinib, Generally Accepted Accounting Principles (United States), BET, Physician, Disease, Pharmaceutical industry, Cryptocurrency

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the second quarter ended June 30, 2021.

Key Points: 
  • Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the second quarter ended June 30, 2021.
  • We are extremely excited by the progress that has been made in the second quarter with the completion of enrollment for our MOMENTUM study, said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer at Sierra Oncology.
  • Second Quarter 2021 Financial Results (all amounts reported in U.S. currency)
    Research and development expenses were $14.1 million for the three months ended June 30, 2021 compared with $10.2 million for the three months ended June 30, 2020.
  • Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.

 Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

Retrieved on: 
Jeudi, août 5, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Momelotinib, MD, Fast Track, Jak, U.S. Securities and Exchange Commission, Webcast, Bachelor of Medicine, Bachelor of Surgery, Anemia, Disease, Private Securities Litigation Reform Act, Security (finance), Development, Cancer, Janus kinase 1, Patient, Bromodomain-containing protein 3, COVID-19, BRD4, ACVR1, Splenomegaly, SEC, Symptoms of COVID-19, Risk, BRD2, Doctor of Philosophy, Janus kinase 2, Research, BRDT, Primary myelofibrosis, Safety, Ruxolitinib, Conference, BET, Nasdaq, International, Pharmaceutical industry, Momelotinib, Sierra Oncology, MOMELOTINIB, SIERRA ONCOLOGY

Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022.

Key Points: 
  • Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022.
  • First, it brings another novel compound into the Sierra development pipeline, expanding our opportunity to deliver transformative therapies for patients with rare cancers.
  • Several BET inhibitors are under clinical investigation in multiple solid tumor and hematologic indications, including myelofibrosis.
  • AZD5153 is a selective BRD4 inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, resulting in improved potency.

Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Jeudi, août 5, 2021
Janus, Chief executive officer, Clinical trial, Research, Jak, Population, Pancreatic cancer, Breast cancer, Bone loss, MK2, Pharmacokinetics, Atopic dermatitis, Psoriasis Area and Severity Index, COVID-19, Hidradenitis suppurativa, Psoriatic arthritis, ACRS, Anno Domini, Safety, Therapy, The New College, Chennai, Nasdaq, Rheumatoid arthritis, GLOBE, Pharmaceutical industry, Medical imaging

WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2021 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2021 and provided a corporate update.
  • Net loss was $18.2 million for the second quarter of 2021 compared to $11.6 million for the second quarter of 2020.
  • Total revenue was $1.8 million for the second quarter of 2021 compared to $2.0 million for the second quarter of 2020.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis

Retrieved on: 
Mardi, juillet 27, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Tyrosine kinases, Branches of biology, Signal transduction, Pharmaceutical industry, Health sciences, Life sciences, Janus kinase inhibitor, Janus kinase, Jak, Boxed warning, Pharmaceutical industry in China, Medication

Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.

Key Points: 
  • Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.
  • That is only a fraction of the total market for anti-inflammatory drugs.
  • The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Retrieved on: 
Mercredi, février 3, 2021
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Enzymes, Tyrosine-protein kinase SYK, Tyrosine kinase, Jak, Drugs, Tyrosine kinase inhibitors, Orphan drugs, Protein kinase inhibitors, Indazoles, Cerdulatinib, Janus kinase inhibitor

Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

Key Points: 
  • Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
  • Patients with CHE suffer greatly from this disease, which limits their ability to work and perform activities of daily living.
  • There are no approved treatments for patients suffering from CHE in the U.S. and in many other major markets.
  • We are pleased that the FDA has granted Fast-Track designation to gusacitinib.

Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting

Retrieved on: 
Samedi, décembre 5, 2020
Clinical medicine, Medicine, Tyrosine kinases, Primary myelofibrosis, Health, Momelotinib, Janus kinase 2, Targeted therapy, Thrombopoietin receptor, Jak, Cancer

"Momelotinib's unique mechanism of actiontargeting JAK1, JAK2 and ACVR1is translating to durability of activity and survival data consistent with its clinical and biologic profile," said Dr. Verstovsek.

Key Points: 
  • "Momelotinib's unique mechanism of actiontargeting JAK1, JAK2 and ACVR1is translating to durability of activity and survival data consistent with its clinical and biologic profile," said Dr. Verstovsek.
  • "As the SIMPLIFY data sets continue to mature, we are seeing increasingly exciting outcomes in terms of overall survival, as well as myelofibrosis disease hallmarks, including splenic response and transfusion independence," said Barbara Klencke, MD, Chief Development Officer at Sierra Oncology.
  • Momelotinib is a selective and orally bioavailable JAK1, JAK2 and ACVR1 inhibitor currently under investigation for the treatment of myelofibrosis.
  • Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.